1.415

1.07% 0.015

Sellas Life Sciences Group Inc (SLS)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché SLS Giù? Forum Previsione Frazionamento azionario

Precedente Chiudi:

$1.40

Aprire:

$1.43

Volume 24 ore:

1.37M

Relative Volume:

0.58

Capitalizzazione di mercato:

$121.97M

Reddito:

Utile/perdita netta:

$-37.34M

Rapporto P/E:

-1.0404

EPS:

-1.36

Flusso di cassa netto:

$-36.91M

1 W Prestazione:

+9.69%

1M Prestazione:

+27.48%

6M Prestazione:

+15.98%

1 anno Prestazione:

-3.08%

Intervallo 1D:

$1.375

$1.45

Intervallo di 1 settimana:

$1.265

$1.47

Portata 52W:

$0.772

$1.84

Sellas Life Sciences Group Inc Stock (SLS) Company Profile

Nome

Sellas Life Sciences Group Inc

Settore

Healthcare (1155)

Industria

Biotechnology (677)

Telefono

(646) 200-5278

Indirizzo

7 TIMES SQUARE, NEW YORK, NY

Dipendente

Cinguettio

Prossima data di guadagno

2024-11-07

Ultimi documenti SEC

SLS's Discussions on Twitter

Confronta SLS con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
SLS Sellas Life Sciences Group Inc	1.41	121.97M	0	-37.34M	-36.91M	-1.36
VRTX Vertex Pharmaceuticals Inc	492.70	122.76B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	607.03	61.38B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	615.31	36.37B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	253.16	30.12B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	250.00	24.70B	3.81B	-644.79M	-669.77M	-6.24

Sellas Life Sciences Group Inc Stock (SLS) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2021-07-21	Iniziato	Cantor Fitzgerald	Overweight
2018-11-01	Iniziato	Oppenheimer	Outperform
2018-04-02	Iniziato	H.C. Wainwright	Buy
2018-03-19	Aggiornamento	Maxim Group	Hold → Buy

Sellas Life Sciences Group Inc Borsa (SLS) Ultime notizie

08:46 AM

SELLAS Unveils Breakthrough Preclinical Data Highlighting - GlobeNewswire

08:46 AM

08:45 AM

Breakthrough: New Cancer Drug SLS009 Extends AML Patient Survival by 252% in Clinical Trial Data - Stock Titan

08:45 AM

Apr 25, 2025

SELLAS Life Sciences Group Inc: Navigating Market Fluctuations with a 127.18M Market Cap - investchronicle.com

Apr 25, 2025

The time has not yet come to remove your chips from the table: SELLAS Life Sciences Group Inc (SLS) - Sete News

Apr 25, 2025

Apr 24, 2025

Ratio Review: Analyzing fuboTV Inc (FUBO)’s Price-to-Cash and Price-to-Free Cash Flow - DWinneX

Apr 24, 2025

Financial Fitness Check: Examining Royalty Pharma plc (RPRX)’s Key Ratios - DWinneX

Apr 24, 2025

SELLAS Life Sciences Group (NASDAQ:SLS) Trading 1.6% Higher – Time to Buy? - Defense World

Apr 24, 2025

Apr 23, 2025

SELLAS Life Sciences Group, Inc. to Present Preclinical Efficacy Data for SLS009 in ASXL1 Mutated Colorectal Cancer at ASCO 2025 Annual Meeting - Nasdaq

Apr 23, 2025

SELLAS to Present at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting - GlobeNewswire

Apr 23, 2025

Clinical Trial Breakthrough: SELLAS Unveils Novel Cancer Drug Results for Hard-to-Treat ASXL1 Mutations - Stock Titan

Apr 23, 2025

Apr 22, 2025

How did SELLAS Life Sciences Group Inc (SLS) fare last session? - uspostnews.com

Apr 22, 2025

Analysts review SELLAS Life Sciences Group Inc’s rating - knoxdaily.com

Apr 22, 2025

Loop Capital analysts downgrades a Sell rating for Canadian National Railway Co (CNI) - knoxdaily.com

Apr 22, 2025

Apr 21, 2025

Analysts Are Recommending SELLAS Life Sciences Group Inc (SLS) As A Buy Candidate - Marketing Sentinel

Apr 21, 2025

Apr 18, 2025

Oncology Breakthroughs: How Cancer Research Is Advancing in 2025 (PR Newswire) - Aktiellt

Apr 18, 2025

Apr 09, 2025

SELLAS reports promising AML treatment trial results - Investing.com

Apr 09, 2025

Apr 08, 2025

SELLAS posts mid-stage trial win for leukemia drug (SLS:NASDAQ) - Seeking Alpha

Apr 08, 2025

Sellas Life Sciences Says Group Data Show Tambiciclib Tops Benchmark for Median Overall Survival in Leukemia Study; Shares Up - MarketScreener

Apr 08, 2025

Sellas Life Sciences Shares Gains On Positive Cohort 3 Phase 2 Results For SLS009 - Nasdaq

Apr 08, 2025

SELLAS reports promising AML treatment trial results By Investing.com - Investing.com India

Apr 08, 2025

SELLAS Announces Positive Overall Survival in Cohort 3 from the Ongoing Phase 2 Trial of SLS009 in r/r AML - GlobeNewswire

Apr 08, 2025

Breakthrough: New Leukemia Drug Shows 8.8-Month Survival vs 2.5-Month Standard - Stock Titan

Apr 08, 2025

Apr 05, 2025

Critical Review: SELLAS Life Sciences Group (NASDAQ:SLS) vs. CV Sciences (OTCMKTS:CVSI) - Defense World

Apr 05, 2025

Apr 02, 2025

Virtu Financial LLC Sells 38,086 Shares of SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) - Defense World

Apr 02, 2025

Mar 31, 2025

Sellas Life Sciences: A Hold For Now With Huge, But Uncertain, Near-Term Catalyst (SLS) - Seeking Alpha

Mar 31, 2025

Mar 28, 2025

Solaris Resources (CVE:SLS) Cut to Hold at Maxim Group - Defense World

Mar 28, 2025

Mar 27, 2025

Sellas Life Sciences Advances in Cancer Treatment Development - TipRanks

Mar 27, 2025

Mar 26, 2025

Analysts Are Bullish on Top Healthcare Stocks: Quince Therapeutics (QNCX), Lucid Diagnostics (LUCD) - The Globe and Mail

Mar 26, 2025

Mar 21, 2025

SELLAS Life Sciences Reports Full Year 2024 Financial Results and Provides Corporate Update - The Manila Times

Mar 21, 2025

Mar 20, 2025

SELLAS LIFE SCIENCES GROUP I Earnings Results: $SLS Reports Quarterly Earnings - Nasdaq

Mar 20, 2025

SELLAS Life Sciences Group, Inc. SEC 10-K Report - TradingView

Mar 20, 2025